The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): A comprehensive approach based on morphology, cytogenetics, and molecular markers

Annals of Hematology

Volumn 87, Issue 1, 2008, Pages 1-10

  Haferlach, Torsten ^a   Bacher, Ulrike ^b   Kern, Wolfgang ^a   Schnittger, Susanne ^a   Haferlach, Claudia ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

BCR ABL; CMPD; Cytomorphology; Molecular marker

Indexed keywords

BCR ABL PROTEIN; HYBRID PROTEIN; IMATINIB; JANUS KINASE 2; MOLECULAR MARKER; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ALGORITHM; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD SMEAR; BONE MARROW BIOPSY; BONE MARROW EXAMINATION; CHROMOSOME 9P; CHROMOSOME BANDING PATTERN; CHRONIC NEUTROPHILIC LEUKEMIA; CYTOGENETICS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; EOSINOPHILIC LEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOHISTOCHEMISTRY; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; MUTATIONAL ANALYSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; STANDARDIZATION; THROMBOCYTHEMIA; TRISOMY 8; WORLD HEALTH ORGANIZATION;

ALGORITHMS; CHROMOSOMES, HUMAN; CYTOGENETICS; HUMANS; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; TUMOR MARKERS, BIOLOGICAL;

EID: 36649011653     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0403-6     Document Type: Review

References (69)

1. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP (2005) JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106:3370-3373
2. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C et al (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162-2168
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790
4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397
5. Tefferi A, Lasho TL, Gilliland G (2005) JAK2 mutations in myeloproliferative disorders. N Engl J Med 353:1416-1417
6. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A et al (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201-1214
7. Gotlib J, Cools J, Malone JM3, Schrier SL, Gilliland DG, Coutre SE (2004) The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for diagnosis, classification, and management. Blood 103:2879-2891
8. Jaffe ES, Harris NL, Stein H, Vardiman JWE (2001) World Health Organization classification of tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon
9. Bench AJ, Cross NC, Huntly BJ, Nacheva EP, Green AR (2001) Myeloproliferative disorders. Best Pract Res Clin Haematol 14:531-551
10. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H et al (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 110:1092-1097
11. Kroger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhauser M, Reiter A, Zabelina T, Zander AR, Fehse B (2007) Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 109:1316-1321
12. Reiter A, Hehlmann R, Goldman JM, Cross NC (1999) The 8p11 myeloproliferative syndrome. Med Klin (Munich) 94:207-210
13. McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B, Oscier D, Polkey MI, Reilly JT, Rosenthal E, Ryan K, Pearson TC et al (2005) Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 130(2):174-195
14. Löffler H, Rastetter J, Haferlach TE (2005) Atlas of clinical hematology, 2nd edition. Springer, Berlin Heidelberg New York
15. Shaw GR (2005) Ringed sideroblasts with thrombocytosis: An uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol 131:180-184
16. Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, Sekeres MA, Maciejewski JP (2006) Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 108:2173-2181
17. Gattermann N, Billiet J, Kronenwett R, Zipperer E, Germing U, Nollet F, Criel A, Selleslag D (2007) High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600×109/l) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood 109:1334-1335
18. Tefferi A, Solberg LA, Silverstein MN (2000) A clinical update in polycythemia vera and essential thrombocythemia. Am J Med 109:141-149
19. Thiele J, Kvasnicka HM (2000) Polyglobuly versus polycythemia vera. Pathologe 21:24-30
20. Thiele J, Kvasnicka HM, Zankovich R, Diehl V (2001) The value of bone marrow histology in differentiating between early stage Polycythemia vera and secondary (reactive) Polycythemias. Haematologica 86:368-374
21. Thiele J, Kvasnicka HM, Orazi A (2005) Bone marrow histopathology in myeloproliferative disorders-current diagnostic approach. Semin Hematol 42:184-195
22. Bacher U, Haferlach T, Kern W, Hiddemann W, Schnittger S, Schoch C (2005) Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann Hematol 84:250-257
23. Bench AJ, Nacheva EP, Champion KM, Green AR (1998) Molecular genetics and cytogenetics of myeloproliferative disorders. Baillieres Clin Haematol 11:819-848
24. Sessarego M, Defferrari R, Dejana AM, Rebuttato AM, Fugazza G, Salvidio E, Ajmar F (1989) Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study. Cancer Genet Cytogenet 43:57-65
25. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW (2001) Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 113:763-771
26. Schnittger S, Bacher U, Kern W, Haferlach T, Haferlach C (2007) JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): A comparative study on 1103 CMPD and 269 AML cases. Leukemia 21:1843-1845
27. Andrieux J, Demory JL, Caulier MT, Agape P, Wetterwald M, Bauters F, Lai JL (2003) Karyotypic abnormalities in myelofibrosis following polycythemia vera. Cancer Genet Cytogenet 140:118-123
28. Bacher U, Haferlach T, Schoch C (2005) Gain of 9p due to an unbalanced rearrangement der(9;18): A recurrent clonal abnormality in chronic myeloproliferative disorders. Cancer Genet Cytogenet 160:179-183
29. Chen Z, Notohamiprodjo M, Guan XY, Paietta E, Blackwell S, Stout K, Turner A, Richkind K, Trent JM, Lamb A, Sandberg AA (1998) Gain of 9p in the pathogenesis of polycythemia vera. Genes Chromosomes Cancer 22:321-324
30. Najfeld V, Montella L, Scalise A, Fruchtman S (2002) Exploring polycythaemia vera with fluorescence in situ hybridization: Additional cryptic 9p is the most frequent abnormality detected. Br J Haematol 119:558-566
31. Mertens F, Johansson B, Heim S, Kristoffersson U, Mitelman F (1991) Karyotypic patterns in chronic myeloproliferative disorders: Report on 74 cases and review of the literature. Leukemia 5:214-220
32. Cross NC, Reiter A (2002) Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 16:1207-1212
33. Campbell PJ, Green AR (2006) The myeloproliferative disorders. N Engl J Med 355:2452-2466
34. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061
35. Steensma DP (2006) JAK2 V617F in myeloid disorders: Molecular diagnostic techniques and their clinical utility: A paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 8:397-411
36. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E et al (2005) The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106:3377-3379
37. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 106:1207-1209
38. Boissinot M, Garand R, Hamidou M, Hermouet S (2006) The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). Blood 108:1781-1782
39. Boissinot M, Lippert E, Girodon F, Dobo I, Fouassier M, Masliah C, Praloran V, Hermouet S (2006) Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood 108:3223-3224
40. De S, V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, Sica S, Leone G (2007) Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 5:708-714
41. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459-468
42. Levine RL, Wernig G (2006) Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program 510:233-239
43. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR et al (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood 108:3472-3476
44. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS 3:e270
45. Bohm J, Schaefer HE (2002) Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease. J Clin Pathol 55:862-864
46. Bohm J, Kock S, Schaefer HE, Fisch P (2003) Evidence of clonality in chronic neutrophilic leukaemia. J Clin Pathol 56:292-295
47. Kako S, Kanda Y, Sato T, Goyama S, Noda N, Shoda E, Oshima K, Inoue M, Izutsu K, Watanabe T, Motokura T, Chiba S et al (2007) Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation. Am J Hematol 82:386-390
48. Mc Lornan DP, Percy MJ, Jones AV, Cross NC, Mc Mullin MF (2005) Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation. Haematologica 90:1696-1697
49. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, Meloni G, Saglio G, Salvatore F, Rotoli B (1996) Neutrophilic-chronic myeloid leukemia: A distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 88:2410-2414
50. Christopoulos C, Kottoris K, Mikraki V, Anevlavis E (1996) Presence of the bcr/abl rearrangement in a patient with chronic neutrophilic leukaemia. J Clin Pathol 49:1013-1015
51. Brito-Babapulle F (2003) The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol 121:203-223
52. Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG (2004) The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol 11:51-57
53. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, Ho CL, Li CY, Dewald GW, Tefferi A (2004) FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104:3038-3045
54. Fletcher S, Bain B (2007) Eosinophilic leukaemia. Br Med Bull 81-82:115-127
55. La Starza R, Specchia G, Cuneo A, Beacci D, Nozzoli C, Luciano L, Aventin A, Sambani C, Testoni N, Foppoli M, Invernizzi R, Marynen P et al (2005) The hypereosinophilic syndrome: Fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica 90:596-601
56. Roche-Lestienne C, Lepers S, Soenen-Cornu V, Kahn JE, Lai JL, Hachulla E, Drupt F, Demarty AL, Roumier AS, Gardembas M, Dib M, Philippe N et al (2005) Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 19:792-798
57. Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D, Herregods MC, Van Hoof A, Selleslag D, Roufosse F, Maerevoet M, Verhoef G et al (2004) Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 18:734-742
58. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX et al (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:481-487
59. Cools J (2005) FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia. Verh K Acad Geneeskd Belg 67:169-176
60. Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A, Roche-Lestienne C, Preudhomme C et al (2007) Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109:4635-4640
61. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, Glassman AB, Albitar M, Kwari MI, Beran M (2002) Prognostic factors and scoring systems in chronic myelomonocytic leukemia: A retrospective analysis of 213 patients. Blood 99:840-849
62. Padua RA, Guinn BA, Al-Sabah AI, Smith M, Taylor C, Pettersson T, Ridge S, Carter G, White D, Oscier D, Chevret S, West R (1998) RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: A 10-year follow-up. Leukemia 12:887-892
63. Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S (2007) A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 92:744-752
64. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M et al (2006) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for myelofibrosis research and treatment (IWG-MRT). Blood 108:1497-1503
65. McMullin MF, Reilly JT, Campbell P, Bareford D, Green AR, Harrison CN, Conneally E, Ryan K (2007) Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol 138:821-822
66. Schnittger S, Bacher U, Kern W, Schroder M, Haferlach T, Schoch C (2006) Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia 20:2195-2197
67. Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G, Kreipe HH (2007) Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 109:4106-4107
68. Lelievre H, Ferrand A, Mozziconacci MJ, Birnbaum D, Delaval B (2006) Myeloproliferative disorders: Premalignant, stem cell, G1 diseases? Leukemia 20:1475-1480
69. Michiels JJ, Thiele J (2002) Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 76:133-145